Ticagrelor and Adenosine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative nucleoside transporter (ENT). This mechanism can contribute to the beneficial effects and to the side effects (dyspnea) of ticagrelor in patients with an acute myocardial infarction. In the current research proposal, we aim to investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.

NCT00380198

Coronary Artery Disease

TERMINATED PHASE3

Eplerenone and Extracellular Adenosine Formation

NCT01837108

Pharmacodynamics

COMPLETED PHASE4

An Interaction Study With Digoxin and AZD1305

NCT00712465

Atrial Fibrillation

COMPLETED PHASE1

Adenosine Cardioplegia; Improved Cardioprotection?

NCT01123525

Angina Pectoris

COMPLETED PHASE1/PHASE2

Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

NCT04632121

Nicorandil

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ticagrelor 180 mg single dose

Group Type ACTIVE_COMPARATOR

Ticagrelor 180 mg single dose

Intervention Type DRUG

Placebo

Placebo single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor 180 mg single dose

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male sex
* Age 18-40 years
* Healthy
* Written informed consent

Exclusion Criteria

* Smoking
* Hypertension (Blood pressure \>140 mmHg and/or \>90 mmHg - SBP/DBP-)
* Diabetes Mellitus (fasting glucose \> 7.0 mmol/L or random \> 11.0 mmol/L)
* History of any cardiovascular disease
* History of chronic obstructive pulmonary disease (COPD) or asthma
* Bleeding tendency
* Concomitant use of medication
* Renal dysfunction (MDRD \< 60 ml/min)
* Liver enzyme abnormalities (ALAT \> twice upper limit of normality)
* Thrombocytopenia (\<150\*109/ml)
* Second/third degree AV-block on electrocardiography

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes